SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition.
Communications biology
Zhou J, Zhu M, Wang Q, Deng Y, Liu N, Liu Y, Liu Q.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2023
Cancer Research
Immunology
No items found.
Key Finding
The study suggests that aromatase inhibitor therapy downregulates SERPINA3 and leads to the ensuing upregulation of ANKRD11, which in turn promotes aromatase inhibitor resistance via binding to and activating HDAC3. HDAC3 inhibition may reverse the aromatase inhibitor resistance in ER-positive breast cancer with decreased SERPINA3 and increased ANKRD11 expression.
Countstar Connection
For the study's cell samples, researchers obtained cell-count measurements with Countstar (model not specified) during quality assessment for the cancer-model experiments.
